The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis.
Saved in:
| Title: | The tolerability of sofosbuvir/velpatasvir for 12 weeks in patients treated in the ASTRAL 1, 2 and 3 studies: A pooled safety analysis. |
|---|---|
| Authors: | Jacobson IM; NYU Langone Health, New York, New York, USA., Bourgeois S; Campus Stuivenberg, Antwerp, Belgium., Mathurin P; Centre Hospitalier Universitaire de Lille, Universite Nord de France, Lille, France., Thuluvath P; Institute for Digestive Health and Liver Disease, Baltimore, Maryland, USA., Ryder SD; NIHR Nottingham Biomedical Research Centre at Nottingham University Hospitals NHS Trust and The University of Nottingham, Queen's Medical Centre Campus, Nottingham, UK., Gerken G; Helios Klinikum Niederberg, Velbert, Germany., Hernandez C; Gilead Sciences Europe LTD, Uxbridge, UK., Vanstraelen K; Gilead Sciences Europe LTD, Uxbridge, UK., Scherbakovsky S; Gilead Sciences, Inc, Foster City, California, USA., Osinusi A; Gilead Sciences, Inc, Foster City, California, USA., Tedesco D; Gilead Sciences, Inc, Foster City, California, USA., Foster GR; Queen Mary University, London, UK. |
| Source: | Journal of viral hepatitis [J Viral Hepat] 2023 May; Vol. 30 (5), pp. 448-454. Date of Electronic Publication: 2023 Mar 02. |
| Publication Type: | Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Blackwell Scientific Publications Country of Publication: England NLM ID: 9435672 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2893 (Electronic) Linking ISSN: 13520504 NLM ISO Abbreviation: J Viral Hepat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
